Combined treatment with sorafenib and kahweol potentiated the cytotoxicity in renal carcinoma cells through down-regulation of Mcl-1 and c-FLIP protein expression in a proteasome-dependent manner. This evidence concerns the gene MCL1 and renal carcinoma.